In contrast, recent preclinical studies established that activation of AR with supraphysiological levels of testosterone (SPT) can also inhibit late-stage, castration-resistant PC (CRPC) by effectively suppressing DNA damage response (DDR) and proliferation (4–6). This evidence concerns the gene AR and pachyonychia congenita.